Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting

References

• Congressional Budget Office (CBO). How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Congress of the United States, July 1998
   Google Scholar
• Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25:1578–92
   PubMed Web of Science ®Google Scholar
• Health Canada. Report C of the Expert Advisory Committee on Bioavailability. Available from http://www.hc-sc.gc.ca/ dhp-mps/prodpharma/applic-demande/guide-ld/bio/biorepc_ biorapc_e.html [Last accessed 8 Nov 8 2006]
   Google Scholar
• Besag FM. Is generic prescribing acceptable in epilepsy? Drug Safety 2000;23:173–82
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs. Available from http://www.fda.gov/cder/ogd/ [Last accessed 8 Aug 2006]
   Google Scholar
• Crawford P, Feely M, Guberman A, et al. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15:165–76
   PubMed Web of Science ®Google Scholar
• Feely M, Crawford P, Krämer G, et al. Risk management in epilepsy: generic substitution and continuity of supply. The European Journal of Hospital Pharmacy Science 2005;11:83–7
   Google Scholar
• Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. Br Med J 1970;4:271–3
   PubMed Web of Science ®Google Scholar
• MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987;37:1885
   PubMed Web of Science ®Google Scholar
• Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA 1987;258:1216–7
   Google Scholar
• Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology 1993;43:2696–7
   Google Scholar
• Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to brand compounds compared to other drug classes. Epilepsia 2007;48:464–9
   PubMed Web of Science ®Google Scholar
• LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology, August 2007 [in press]
   Google Scholar
• Argumosa A, Herranz JL. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol 2005;41:45–9
   PubMed Web of Science ®Google Scholar
• Crawford P, Hall WW, Chappell B, et al. Generic prescribing for epilepsy. Is it safe? Seizure 1996;5:1–5
   PubMed Web of Science ®Google Scholar
• Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 2004;18:617–28
   PubMed Web of Science ®Google Scholar
• Duh MS, Andermann F, Paradis PE, et al. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. Dis manag 2007;10:216–25
   PubMedGoogle Scholar
• American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990;40:1641–3
   PubMed Web of Science ®Google Scholar
• Liow K, Barkley GL, Pollard JR, et al.; American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249–50
   Google Scholar
• Perucca E, Albani F, Capovilla G, et al. Recommendations of the Italian League Against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 2006;47(Suppl 5):16–20
   PubMedGoogle Scholar
• American Society of Health-System Pharmacists; comments from the FDA on narrow therapeutic index drugs and Generic Substitution, 4/1/1998. Available from http://www.ashp.org/s_ ashp/sec_press_article.asp?CID=168&DID=2023&id=153 [Last accessed 27 Feb 2007]
   Google Scholar
• Berg M. What’s the problem with generic antiepileptic drugs? A call to action. Neurology 2007;68:1245–6
   PubMed Web of Science ®Google Scholar
• Heaney D, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007;6:465–8
   PubMed Web of Science ®Google Scholar
• Association Quebecoise des Etablissements de Santé et de Services Sociaux (AQESSS), Systeme integre d’analyse de la performance (SIAP), 2004–2005
   Google Scholar
• Statistics Canada, Table 326–0002, Survey IPC-2301, 2007
   Google Scholar
• U.S. Census Bureau. Census statistics, 2006
   Google Scholar
• Canadian Institute for Health Information (CIHI), Health Service Statistics, 2006
   Google Scholar
• Organization for Economic Co-operation and Development (OECD), OECD health data 2006, October 6th edn
   Google Scholar
• Organization for Economic Co-operation and Development (OECD), EUROSTAT-OECD Methodological manual on purchasing power parities (PPPs), 2005 edn
   Google Scholar
• Patented Medicine Prices Review Board (PMPRB), Canada. Non-patented prescription drug prices reporting: Canadian and foreign price trends. ISSN 1911–0014, 2006, p.52
   Google Scholar
• Bank of Canada, rates and statistics. Available from http://www.bank-banque-canada.ca/en/rates/exchange.html [Last accessed 12 Jan 2007]
   Google Scholar
• Red Book Pharmacy’s Fundamental Reference, 2004 and 2005 edn. Montvale: Thomson
   Google Scholar
• Kaiser Family Foundation. Prescription drug trends. Fact Sheet #3057–04, November, 2005. Available from http://www.kff.org
   Google Scholar
• Health care cost and utilization project (HCUP). The Nationwide Inpatient Sample (NIS) Statistics, Agency for Health care Research and Quality, 2004
   Google Scholar
• Bureau of Labor Statistics. consumer price index detailed report tables 1–29, December 2006. Available from http://www.bls. gov/cpi/cpid0612.pdf [Last accessed 26 Jan 2007]
   Google Scholar
• Frost F, Hurley J, Petersen H, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000;41:1020–6
   PubMed Web of Science ®Google Scholar
• Kotsopoulos I, Evers S, Ament A, et al. Estimating the cost of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 2001;42:634–40
   PubMed Web of Science ®Google Scholar